In Vitro Diagnostics (IVD) include reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. The reagents, instruments, and systems are used in the collection, preparation, and examination of specimens taken from the human body. This includes Cardiac Disease, Hematological Disorders, Hormonal Disorders, Metabolic Disorder, Infectious Disease, IVD Analyzers, Oncology and Reproductive Health Diagnostics. Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) gene tests are carried out to detect gene rearrangements in Non-Small Cell Lung Cancer (NSCLC) tumor cells; the outcome of which may guide therapies to treat NSCLC. GlobalData uses proprietary data and analytics to provide a comprehensive report on the alk tests devices market, including market shares of different players within Switzerland. Buy the latest report here.
In 2023, GlobalData’s Market Model methodology determined that the leading player in the alk tests market in Switzerland was Abbott Laboratories followed by ZytoVision, Qiagen, F. Hoffmann-La Roche, Biocare Medical, Thermo Fisher Scientific, Agilent Technologies, Amoy Diagnostics, Sysmex, EntroGen, Danaher, New England Biolabs, Bio-Rad Laboratories, HLB PanaGene and Cancer Diagnostics.
ALK Tests include ALK Immunohistochemistry Tests, ALK In Situ Hybridisation Tests, and ALK Nucleic Acid Amplification Tests (NAATs).
The value of the alk tests devices market within Switzerland was expected to be over $0.1m in 2023.
For the latest complete market share analysis of alk tests device market in Switzerland, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.